

RSV Vaccine: Error alert

The introduction of new vaccine products can increase the risk of vaccine administration errors. Immunisation providers must ensure that a vaccine is clinically appropriate for the patient prior to administration.

Category	Vaccine/Product	Eligibility	Access	Funding	Recommendation
Infant RSV Immunisation	Beyfortus™ (nirsevimab)	Infants from birth to less than 8 months of age are recommended to receive a dose of nirsevimab if they meet one of the listed eligibility criteria.	Offered in hospital at birth. For catch-up: GPs, community immunisation services	Funded by Queensland Health only. Beyfortus™ is not available on the private market.	Single dose for eligible infants. 50mg (<5kg) or 100mg (≥5kg).
		Children with a condition associated with increased risk of severe RSV from 8 <24 months of age , ahead of their second RSV season.	GPs, community immunisation services, specialist services.		Single dose for eligible young children before their 2nd RSV season (regardless of previous doses). 200mg (2x100mg) regardless of weight.
Maternal RSV Vaccine	Abrysvo® only	During pregnancy between 28–36 weeks gestation.	GP, pharmacy, community immunisation services, some maternity and obstetric services.	NIP-funded.	Single dose during pregnancy to protect infants via passive immunity.
Adult RSV Vaccine (excluding pregnancy)	Arexvy® or Abrysvo®	Adults aged ≥60 years (especially ≥75 years).	GP, pharmacy, community immunisation services, some maternity and obstetric services.	Not funded by Queensland Health. Vaccine available to consumers on private prescription only. Uptake data is monitored by Queensland Health.	Single dose before RSV season for adults aged ≥75 years.